DexamethasoneInsulin resistance and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1911卷 / 1期

关键词：

D O I：

10.1007/s40278-022-17470-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：173 / 173

相关论文

共 50 条

[31] Multiple drugsDrug resistance, lack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1869 (1) : 240 - 240
[32] Multiple drugsLack of efficacy, drug resistance and off-label use: case report
Reactions Weekly, 2021, 1869 (1) : 247 - 247
[33] AntineoplasticsVarious toxicities and acquired resistance following off-label use: case report
Reactions Weekly, 2021, 1843 (1) : 48 - 48
[34] Crizotinib/larotrectinib/selitrectinibAcquired resistance following off-label use: case report
Reactions Weekly, 2021, 1852 (1) : 145 - 145
[35] Multiple drugsVarious toxicities, off-label use and no response to off-label therapy: case report
Reactions Weekly, 2021, 1861 (1) : 232 - 232
[36] NivolumabFever following off-label use: case report
Reactions Weekly, 2016, 1601 (1) : 186 - 186
[37] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 47 - 47
[38] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176
[39] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[40] Paclitaxel/vemurafenibMyelosuppression and off-label use: case report
Reactions Weekly, 2022, 1888 (1) : 292 - 292

← 1 2 3 4 5 →